AGILE THERAPEUTICS INC (AGRX)

US00847L3087 - Common Stock

0.6022  +0.06 (+10.11%)

After market: 0.2408 -0.36 (-60.01%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AGILE THERAPEUTICS INC

NASDAQ:AGRX (3/25/2024, 8:08:50 PM)

After market: 0.2408 -0.36 (-60.01%)

0.6022

+0.06 (+10.11%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-74.91%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap1.51M
Shares
PEN/A
Fwd PE0.89
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AGRX Daily chart

Company Profile

Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 22 full-time employees. The company went IPO on 2014-05-22. The Company’s sole approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla is a method of contraception for use in women of reproductive potential for whom a combined hormonal contraceptive is appropriate. Twirla is a prescription combined hormonal contraceptive patch, which contains the active ingredients ethinyl estradiol (EE), which is a synthetic estrogen and levonorgestrel (LNG), which is a type of progestin. Twirla delivers 30 micrograms of EE per day, a dose of EE consistent with the dose delivered by many commonly prescribed oral contraceptives. The firm commercializes Twirla in the United States. Twirla leverages the Company’s transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability.

Company Info

AGILE THERAPEUTICS INC

500 College Road East, Suite 310

Princeton NEW JERSEY 08540

P: 16096831880

CEO: Alfred Altomari

Employees: 22

Website: https://www.agiletherapeutics.com/

AGRX News

News Imagea month ago - BusinessInsiderAGRX Stock Earnings: Agile Therapeutics Misses EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Agile Therapeutics (NASDAQ:AGRX) just reported results for the first quarter of...

News Imagea month ago - InvestorPlaceAGRX Stock Earnings: Agile Therapeutics Misses EPS, Beats Revenue for Q1 2024

AGRX stock results show that Agile Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

News Imagea month ago - Agile Therapeutics, Inc.Agile Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
News Image3 months ago - InvestorPlaceAGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023

AGRX stock results show that Agile Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.

News Image3 months ago - BusinessInsiderAGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Agile Therapeutics (NASDAQ:AGRX) just reported results for the fourth quarter o...

News Image3 months ago - Agile Therapeutics, Inc.Agile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update

AGRX Twits

Here you can normally see the latest stock twits on AGRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example